Richard Herrmann
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.
Journal: Therapeutic advances in medical oncology
Published: July 05, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 08, 2017
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Journal: The Lancet. Oncology
Published: June 20, 2017
Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.
Journal: Clinical colorectal cancer
Published: June 03, 2016
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 22, 2015
Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study.
Journal: BMC cancer
Published: March 31, 2014
Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.
Journal: Oncology research and treatment
Published: December 16, 2013
Clinical benefit response in pancreatic cancer trials revisited.
Journal: Oncology research and treatment
Published: October 29, 2013
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 11, 2013
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Journal: The Lancet. Oncology
Published: November 17, 2012
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 09, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026